-----Original Message-----
From: NIH news releases and news items [mailto:[log in to unmask]] On
Behalf Of NIH OLIB (NIH/OD)
Sent: June 12, 2012 10:44
To: [log in to unmask]
Subject: FIVE MORE PHARMACEUTICAL COMPANIES JOIN NIH INITIATIVE TO SPEED
THERAPEUTIC DISCOVERY
U.S. Department of Health and Human Services NATIONAL INSTITUTES OF HEALTH
NIH News National Center for Advancing Translational Sciences (NCATS)
<http://ncats.nih.gov/> Embargoed for Release: Tuesday, June 12, 2012, 10
a.m. EDT
CONTACT: NCATS Office of Communications, 301-435-0888,
<e-mail:[log in to unmask]>
FIVE MORE PHARMACEUTICAL COMPANIES JOIN NIH INITIATIVE TO SPEED THERAPEUTIC
DISCOVERY Nearly 60 compounds from industry collaborators now publicly
available
Five additional pharmaceutical companies have joined a National Institutes
of Health-led effort to help scientists research promising new treatments
for patients. Funding and molecular compound information is available now
for the initial phase of the recently unveiled Discovering New Therapeutic
Uses for Existing Molecules
<http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeuti
c-uses/therapeutic-uses.html> program. This NIH-industry collaboration will
match researchers with 58 compounds to test ideas for new therapeutic uses.
Since the launch of the program last month, the total number of compounds
the companies are making available has more than doubled.
Abbott, Bristol-Myers Squibb Company, GlaxoSmithKline, Janssen
Pharmaceutical Research & Development, L.L.C., and Sanofi have joined
Pfizer, AstraZeneca, and Eli Lilly and Company in this innovative approach
to research.
The NIH's new National Center for Advancing Translational Sciences (NCATS)
created the Therapeutics Discovery program to help re-engineer the research
pipeline. By crowdsourcing compounds that already have cleared several key
steps in the development process, including safety testing in humans,
scientists nationwide have the opportunity to contribute their expertise to
advancing these resources for new disease therapies.
The eight participating companies will provide their compounds and related
data, which were determined by the NIH to meet specific eligibility
criteria. For example, each compound must have advanced to clinical studies
but been unsuccessful in its original therapeutic indication or not pursued
for business reasons. Preliminary information about the compounds, including
mechanism of action, route of administration, and any limitations in use
based on safety and tolerability, are available at
<http://ncats.nih.gov/therapeutics-directory.html>.
"Each company participating in this innovative collaboration has made
substantial research and development investments to advance these compounds
to the point where they can be used in clinical studies," said Kathy L.
Hudson, Ph.D., NCATS acting deputy director. "If researchers funded through
this effort can demonstrate new uses for the compounds, they could
significantly reduce the amount of time it takes to get a treatment to
patients in need."
For the pilot phase of the program, in fiscal year 2013, NCATS will provide
up to $20 million to fund two- to three-year staged, cooperative agreement
research grants. If specific milestones are met, funded researchers will
conduct pre-clinical validation and clinical feasibility studies in the
first stage, and proof-of-concept clinical trials in the second stage, to
test whether one of the compounds may be effective against a previously
unexplored disease target. The pilot phase also is intended to test the
utility of the newly created template agreements
<http://www.ncats.nih.gov/research/reengineering/rescue-repurpose/therapeuti
c-uses/agreements.html> by reducing the negotiation time that otherwise
could delay the research.
Researchers who are interested in NCATS' Therapeutics Discovery funding must
submit a pre-application in response to the NIH Funding Opportunity
Announcement at
<http://grants.nih.gov/grants/guide/pa-files/PAR-12-203.html> by Aug. 14,
2012. Applicants must include details about how they would explore specific
hypotheses related to one of the compounds that might be useful in a
specific disease area. The pre-applications will undergo review by external
experts, and while no funding will be provided at this stage, successful
applicants will be notified to submit a full application for fiscal year
2013 funding.
For more information, visit <ncats.nih.gov/therapeutics.html>.
The National Center for Advancing Translational Sciences (NCATS) aims to
catalyze the generation of innovative methods and technologies that will
enhance the development, testing and implementation of diagnostics and
therapeutics across a wide range of human diseases and conditions. For more
information about NCATS, visit <ncats.nih.gov>.
About the National Institutes of Health (NIH): NIH, the nation's medical
research agency, includes 27 Institutes and Centers and is a component of
the U.S. Department of Health and Human Services. NIH is the primary federal
agency conducting and supporting basic, clinical, and translational medical
research, and is investigating the causes, treatments, and cures for both
common and rare diseases. For more information about NIH and its programs,
visit <www.nih.gov>.
NIH...Turning Discovery into Health
##
This NIH News Release is available online at:
<http://www.nih.gov/news/health/jun2012/ncats-12.htm>.
To subscribe (or unsubscribe) from NIH News Release mailings, go to
<http://service.govdelivery.com/service/subscribe.html?code=USNIH_1>.
If you subscribed via the NIH Listserv, go to
<https://list.nih.gov/cgi-bin/wa.exe?A0=nihpress>.
-----------------------
To change your mail settings or leave the C-PALSY list, go here:
http://listserv.icors.org/SCRIPTS/WA-ICORS.EXE?SUBED1=c-palsy
|
